ArticleResearch square2024
Chromogranin A Deficiency Attenuates Tauopathy by Altering Epinephrine-Alpha-Adrenergic Receptor Signaling.
Sushil Mahata, Suborno Jati, Daniel Munoz-Mayorga, Shandy Shahabi, Kechun Tang, Yuren Tao, Dennis Dickson, Irene Litvan, Gourisankar Ghosh, Xu Chen
Abstract readPreprint
In one paragraphArticle in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors.
Suborno JatiUniversity of California San Diego.
Daniel Munoz-MayorgaUniversity of California San Diego.
Shandy ShahabiUniversity of California, San Diego.
Kechun TangUniversity of California San Diego.
Yuren TaoUniversity of California San Diego.
Irene LitvanUniversity of California San Diego.
Funding
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9MDementia with Lewy Bodies Consortium - Supplement for ASL sequenceU01NS100610 · NINDS · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI DOUGLAS R GALASKO, JAMES Bruce LEVERENZ · 2016 to 2026
$15.6MU of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0MInvestigation of Gene Regulation by NF-kappaB Transcription factorsR01GM085490 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, GOURISANKAR · 2009 to 2023
$3.8MAssessing skin biomarkers for preclinical diagnosis of PD and non-PD ParkinsonismU01NS112010 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI CHEN, SHU G., GUNZLER, STEVEN A. · 2019 to 2023
$3.7MMechanisms by which the ketone body β-hydroxybutyrate counteracts tau pathogenesisR01AG074273 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Xu Chen · 2022 to 2026
$2.7MRole of Testosterone in Modulating Tau Pathogenesis in FemalesR01AG078185 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Xu Chen · 2022 to 2026
$2.7MSuppressing Inflammation by Blocking IKK OligomerR01AI163327 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GOURISANKAR GHOSH · 2022 to 2026
$2.6MTraining in Research to Assure Neuroscience Scholars Cultivate Expertise in Notable Disparities Science (TRANSCENDS)R25NS098999 · NINDS · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI BRUCE OVBIAGELE · 2017 to 2026
$2.5MIllumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600kThe Role of Chromogranin A in TauopathyR21AG072487 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, XU, GHOSH, GOURISANKAR · 2021 to 2021
$434kReal-Time L-Dopa Monitoring for Improved Management of Parkinson DiseaseR21NS114764 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITVAN, IRENE, WANG, JOSEPH · 2020 to 2020
$434kNIAID NIH HHS R01 AI163327NIA NIH HHS R01 AG074273NIA NIH HHS R01 AG078185NIA NIH HHS R21 AG072487NIA NIH HHS R21 AG078635NIA NIH HHS U19 AG063911NIGMS NIH HHS R01 GM085490NIH HHS S10 OD026929NINDS NIH HHS P30 NS047101NINDS NIH HHS R21 NS114764NINDS NIH HHS R25 NS098999NINDS NIH HHS U01 NS100610NINDS NIH HHS U01 NS112010
6 · The paper itselfAbstract
Metabolic disorders such as insulin resistance and hypertension are potential risk factors for aging and neurodegenerative diseases. These conditions are reversed in Chromogranin A knockout (CgA-KO) mice. This study investigates the role of CgA in Alzheimer's disease (AD) and corticobasal degeneration (CBD). CgA ablation in tauopathy mice (hTau) (CgA-KO/hTau) exhibited reduced tau aggregation, spreading, extended lifespan, and improved cognitive function. Transcriptomic and metabolite analysis of mouse cortices revealed altered alpha1-adrenergic receptors (Adra1) and high epinephrine (EPI) levels in hTau mice compared to WT mice, mirroring observations in AD and CBD patients. CgA-KO/hTau mice exhibited a reversal of EPI levels in the cortex and the expression of Adra1, nearly returning them to WT levels. Treatment of hippocampal slices with EPI or Adra1 agonist intensified, while an Adra1 antagonist inhibited tau hyperphosphorylation and aggregation. These findings highlight the interplay between the EPI-Adra signaling system and CgA in tauopathy.
Identifiers
PMID39149499
PMCPMC11326371
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390